Literature DB >> 32092703

Non-motor symptoms and striatal dopamine transporter binding in early Parkinson's disease.

Rui Liu1, David M Umbach2, Alexander I Tröster3, Xuemei Huang4, Honglei Chen5.   

Abstract

BACKGROUND: Non-motor symptoms (NMS) are common in Parkinson's disease (PD), but their relationships to nigrostriatal degeneration remain largely unexplored.
METHODS: We evaluated 18 NMS scores covering 5 major domains in relation to concurrent and future dopamine transporter (DAT) imaging in 344 PD patients from the Parkinson's Progression and Markers Initiative (PPMI). We standardized NMS assessments into z-scores for side-by-side comparisons. Patients underwent sequential DaTSCAN imaging at enrollment and at months 12, 24, and 48. Specific binding ratios (SBR) were calculated using the occipital lobe reference region. We evaluated the association of striatal DAT binding at the four time points with each baseline NMS using mixed-effects regression models.
RESULTS: Multiple baseline NMS were significantly associated with DAT binding at baseline and at follow-up scans. REM sleep behavior disorder (RBD) symptoms showed the strongest association - mean striatal SBR declined with increasing RBD symptom z-score (average of time-point-specific slopes per unit change in z-score: βAVG = -0.083, SE = 0.017; p < 0.0001). In addition, striatal DAT binding was linearly associated with increasing baseline z-scores: positively for the memory (βAVG=0.055, SE = 0.022; p = 0.01) and visuospatial (βAVG=0.044, SE = 0.020; p = 0.03) cognitive domains, and negatively for total anxiety (βAVG= -0.059, SE = 0.018; p = 0.001). Striatal DAT binding showed curvilinear associations with odor identification, verbal discrimination recognition, and autonomic dysfunction z-scores (p = 0.001, p = 0.0009, and p = 0.0002, respectively). Other NMS were not associated with DAT binding.
CONCLUSIONS: Multiple NMS, RBD symptoms in particular, are associated with nigrostriatal dopaminergic changes in early PD.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dopamine transporter binding; Non-motor symptoms; Parkinson's disease

Mesh:

Substances:

Year:  2020        PMID: 32092703      PMCID: PMC7222918          DOI: 10.1016/j.parkreldis.2020.02.001

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  30 in total

Review 1.  Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease.

Authors:  Ronald B Postuma; Dag Aarsland; Paolo Barone; David J Burn; Christopher H Hawkes; Wolfgang Oertel; Tjalf Ziemssen
Journal:  Mov Disord       Date:  2012-04-15       Impact factor: 10.338

2.  Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings.

Authors:  Lama M Chahine; Daniel Weintraub; Keith A Hawkins; Andrew Siderowf; Shirley Eberly; David Oakes; John Seibyl; Matthew B Stern; Kenneth Marek; Danna Jennings
Journal:  Mov Disord       Date:  2015-08-21       Impact factor: 10.338

3.  Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort.

Authors:  Danna Jennings; Andrew Siderowf; Matthew Stern; John Seibyl; Shirley Eberly; David Oakes; Kenneth Marek
Journal:  JAMA Neurol       Date:  2017-08-01       Impact factor: 18.302

4.  Motor and non-motor correlates of olfactory dysfunction in Parkinson's disease.

Authors:  Henk W Berendse; Dareia S Roos; Pieter Raijmakers; Richard L Doty
Journal:  J Neurol Sci       Date:  2011-06-25       Impact factor: 3.181

5.  Cognitive-nigrostriatal relationships in de novo, drug-naïve Parkinson's disease patients: a [I-123]FP-CIT SPECT study.

Authors:  Flavio Nobili; Claudio Campus; Dario Arnaldi; Fabrizio De Carli; Gaia Cabassi; Andrea Brugnolo; Barbara Dessi; Silvia Morbelli; Gianmario Sambuceti; Giovanni Abbruzzese; Guido Rodriguez
Journal:  Mov Disord       Date:  2010-01-15       Impact factor: 10.338

6.  Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study.

Authors:  Kenn Freddy Pedersen; Jan Petter Larsen; Ole-Bjorn Tysnes; Guido Alves
Journal:  JAMA Neurol       Date:  2013-05       Impact factor: 18.302

7.  Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study.

Authors:  Alex Iranzo; Eduard Tolosa; Ellen Gelpi; José Luis Molinuevo; Francesc Valldeoriola; Mónica Serradell; Raquel Sanchez-Valle; Isabel Vilaseca; Francisco Lomeña; Dolores Vilas; Albert Lladó; Carles Gaig; Joan Santamaria
Journal:  Lancet Neurol       Date:  2013-04-03       Impact factor: 44.182

8.  Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease.

Authors:  Kara M Smith; Sharon X Xie; Daniel Weintraub
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-11-03       Impact factor: 10.154

9.  Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT.

Authors:  K Stiasny-Kolster; Y Doerr; J C Möller; H Höffken; T M Behr; W H Oertel; G Mayer
Journal:  Brain       Date:  2004-11-17       Impact factor: 13.501

10.  Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study.

Authors:  Mike A Nalls; Cory Y McLean; Jacqueline Rick; Shirley Eberly; Samantha J Hutten; Katrina Gwinn; Margaret Sutherland; Maria Martinez; Peter Heutink; Nigel M Williams; John Hardy; Thomas Gasser; Alexis Brice; T Ryan Price; Aude Nicolas; Margaux F Keller; Cliona Molony; J Raphael Gibbs; Alice Chen-Plotkin; Eunran Suh; Christopher Letson; Massimo S Fiandaca; Mark Mapstone; Howard J Federoff; Alastair J Noyce; Huw Morris; Vivianna M Van Deerlin; Daniel Weintraub; Cyrus Zabetian; Dena G Hernandez; Suzanne Lesage; Meghan Mullins; Emily Drabant Conley; Carrie A M Northover; Mark Frasier; Ken Marek; Aaron G Day-Williams; David J Stone; John P A Ioannidis; Andrew B Singleton
Journal:  Lancet Neurol       Date:  2015-08-10       Impact factor: 44.182

View more
  3 in total

1.  Progressive Prefrontal Cortex Dysfunction in Parkinson's Disease With Probable REM Sleep Behavior Disorder: A 3-Year Longitudinal Study.

Authors:  Xiuqin Jia; Wentao Fan; Zhijiang Wang; Yuehong Liu; Ying Li; Haibin Li; Hui Li; Ting Ma; Jing Wang; Qi Yang
Journal:  Front Aging Neurosci       Date:  2022-01-10       Impact factor: 5.750

Review 2.  Dopamine Transporter Imaging, Current Status of a Potential Biomarker: A Comprehensive Review.

Authors:  Giovanni Palermo; Sara Giannoni; Gabriele Bellini; Gabriele Siciliano; Roberto Ceravolo
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

3.  Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial.

Authors:  Charity G Patterson; Elizabeth Joslin; Alexandra B Gil; Wendy Spigle; Todd Nemet; Lana Chahine; Cory L Christiansen; Ed Melanson; Wendy M Kohrt; Martina Mancini; Deborah Josbeno; Katherine Balfany; Garett Griffith; Mac Kenzie Dunlap; Guillaume Lamotte; Erin Suttman; Danielle Larson; Chantale Branson; Kathleen E McKee; Li Goelz; Cynthia Poon; Barbara Tilley; Un Jung Kang; Malú Gámez Tansey; Nijee Luthra; Caroline M Tanner; Jacob M Haus; Giamila Fantuzzi; Nikolaus R McFarland; Paulina Gonzalez-Latapi; Tatiana Foroud; Robert Motl; Michael A Schwarzschild; Tanya Simuni; Kenneth Marek; Anna Naito; Codrin Lungu; Daniel M Corcos
Journal:  Trials       Date:  2022-10-06       Impact factor: 2.728

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.